CTRI/2021/08/035907已完成3 期
A Comparative, Double-Blind, Randomized, Multicenter, Phase III study to compare the safety & efficacy of ENZ105 of Enzene Biosciences Ltd. with Innovator Ranibizumab in subjects with Neovascular (Wet) Age related Macular Degeneration (AMD).
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 152
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Willing to provide voluntary written informed consent.2.Male or female participant with age greater than or equal to 50 years at the time of screening.3.Subjects with treatment-naive CNV (choroidal neovascularization) secondary to AMD, involving the foveal center.4.Have a best corrected visual acuity of 20/40 to 20/320 using Early Treatment Diabetic Retinopathy Study chart- ETDRS (Snellen equivalent) in the study eye.5.Willing and able to comply with protocol.
排除标准
- •1.Known hypersensitivity to Ranibizumab or any of the components of study medication. 2. Prior treatment with any intravitreal drug, verteporfin or photodynamic therapy in the study eye in the past (except for extrafoveal laser photocoagulation in the study eye) and/or non-study eye within past 3 months before enrollment in the study. 3. Laser photocoagulation in the study eye within 1 month before screening the subject. 4. Subject with vision only in one eye. 5. Prior treatment with any anti-VEGF therapy in last 6 months 6. Subfoveal fibrosis or Subfoveal atrophy in the study eye. 7. CNV in either of the two eyes due to causes other than AMD such as histoplasmosis or pathological myopia etc. 8. Retinal pigment epithelial tear involving the macula in the study eye. 9. Any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the study period or that could contribute to a loss of best corrected visual acuity over the study period (e.g. diabetic retinopathy, cataract, uncontrolled glaucoma, uveitis, previous corneal transplant, recent cataract surgery etc.). The decision regarding exclusion is to be based on the opinion of the investigator. 10. Presence of any uncontrolled systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus etc.) 11. Known history of peripheral vasculopathy, peripheral arterial disease within 01 year of study participation 12. Subject with Polypoidal choroidal vasculopathy. 13.Active intraocular inflammation or active/suspected ocular or periocular infection in the study eye. 14. History of retinal or intraocular surgery in the study eye in the last three months. 15. Vitreous hemorrhage in the study eye or history of retinal detachment or macular hole (stage 3 or 4) in the study eye. 16. Any other retinal pathology i.e. Central retinal vein occlusion, Central retinal artery occlusion etc. 17. Pregnant or breastfeeding. 18. Subjects with suspected signs and symptoms of COVID-19/ confirmed novel coronavirus infection (COVID-19) or with history of travel / contact with any COVID-19 positive patient/isolation/quarantine.
研究者
相似试验
已完成
3 期
A Comparative, Randomized, Single Blind, Multicentric, Prospective Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Tapentadol Tablets 100 mg Vs Tramadol Hydrochloride Tablets 50 mg in patients of Osteoarthritis and Post Operative Pain after Orthopaedic SurgeryCTRI/2010/091/002972Ajanta Pharma Ltd200
已完成
3 期
A Clinical study to evaluate the Efficacy, Safety of Fimasartan Tablets Vs Losartan Tablets in Patients with Mild Essential Hypertension.CTRI/2017/08/009242Ajanta Pharma Ltd206
已完成
3 期
A clinical Trial in patients for ocular surface anesthesia during ophthalmologic procedures. Clinical trial is to study efficacy, safety and tolerability of Lidocaine Hydrochloride Ophthalmic Gel 3.5% in comparison to Akten (reference product).CTRI/2009/091/000830Ajanta Pharma Ltd200
已完成
3 期
A clinical Trial in patients with Glaucoma. Clinical trial is to study efficacy, safety and tolerability of Tafluprost Ophthalmic solution in comparison to Latanoprost eye drop (reference product).CTRI/2010/091/001459Ajanta Pharma Ltd200
已完成
3 期
A clinical Trial in patients with Steroid Responsive Inflammatory Ocular Conditions. Clinical trial is to study efficacy, safety and tolerability of Moxifloxacin HCL + Difluprednate Ophthalmic Solution V/S Moxifloxacin HCL+ Dexamethasone Phosphate Eye Drops.CTRI/2010/091/001121Ajanta Pharma Ltd200